Advisory Committee of the Food and Drug Administration to Discuss SEFELSA™ New Drug Application for the Treatment of Moderate to Severe Vasomotor Symptoms Conference Call Later Today NEWARK, Calif. , March 4, 2013 /PRNewswire/ --  Depomed, Inc. (NASDAQ:DEPO) announced that NASDAQ has halted trading

MENLO PARK, Calif. - October 11, 2010 - Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a clinical grant by The Michael J. Fox Foundation under its Clinical Intervention Awards 2010 program.  The modest grant amount supports Depomed in the development of a gastric retentive

MENLO PARK, Calif.--(BUSINESS WIRE)--July 23, 2008--Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a preclinical grant by The Michael J. Fox Foundation under the foundation's Therapeutics Development Initiative 2008 Program. The modest grant amount supports Depomed in the